RxDoctor Payments Data

Abram Burgher, MD

Interventional Pain Medicine · Phoenix, AZNPI 1942274105

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,102 of the $15,467 with a category attached, or 65.3%. 42 manufacturers reported payments, led by Biotronik Inc. at 25.7% of the total. Reporting peaked in 2021 at $5,140 and has fallen 75.9% since, to $1,237 in 2025.

$15,467in general payments, 2019–2025

Across 387 payments — averaging $39.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$4K
  • Nevro Corp.$2K
  • Abbott$2K
  • Surgentec$1K
  • Boston Scientific$1K
  • Medtronic$862
  • plus $4K from 36 others
$6,514,493in research payments, 2019–2025

Across 833 payments — averaging $7820.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$3.3M
  • Pfizer$2.2M
  • GSK$371K
  • Johnson & Johnson$290K
  • Janssen Research & Development, LLC$131K
  • SPR Therapeutics, Inc$121K
  • plus $119K from 6 others
$109,231in ownership & investment interests, 2019–2025

Across 6 payments — averaging $18,205 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spinal Simplicity, LLC$109K

What the payments were for

  • Consulting fees$4,47529%
  • Travel & lodging$8495%
  • Food & beverage$10,10265%
  • Education$210%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,467 in reported general payments places this provider in the 70th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$566,158
Medicare patients
397
Services billed
2,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen98$2,443
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$2,056
Naloxone Hcl25$1,398
Oxycodone Hcl49$853
Tramadol Hcl58$809
Gabapentin28$601
Tizanidine Hcl27$386
Hydromorphone Hcl35$366
Mupirocin45$352
Pregabalin12$318
Morphine Sulfate ErMorphine Sulfate16$302
Ondansetron Hcl12$245
Methocarbamol11$151

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →